A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.

Kanwal Pratap Singh Raghav,Shannon McDonough,Benjamin R. Tan,Crystal S. Denlinger,Anthony Martin Magliocco,Nicholas Choong,Nicolas Sommer,Frank A. Scappaticci,Danae Campos,Katherine A. Guthrie,Scott Kopetz,Marwan Fakih,Howard S. Hochster

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.

2018

Kanwal Pratap Singh Raghav
Shannon McDonough
Benjamin R. Tan
Crystal S. Denlinger
Anthony Martin Magliocco
Nicholas Choong
Nicolas Sommer
Frank A. Scappaticci
Danae Campos
Katherine A. Guthrie
Scott Kopetz
Marwan Fakih
Howard S. Hochster

TPS3620Background: Despite advances in systemic therapy, few patients are cured, creating a large unmet need for strategies targeting novel signaling and resistance pathways. The HER2 pathway, whic...

Keywords:

Cetuximab
HER2 Amplification
Phases of clinical research
Trastuzumab
Pathology
Pertuzumab
Colorectal cancer
Oncology
Irinotecan
Medicine
Internal medicine
Systemic therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations